A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Public ClinicalTrials.gov record NCT01369433. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Open-label, multi-center, multi-national rollover study to allow continued access to tivozanib for subjects who have participated in other tivozanib (monotherapy or combination) protocols. Eligible subjects will continue to receive tivozanib at the same dose and schedule as per the original (parent) protocol. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the (original) parent protocol. Subjects will be seen by the investigator every 4 weeks (± 5 days). Adverse events and blood pressure will be recorded. At the beginning of Cycle 1 and at the beginning of every odd-numbered cycle (Cycle 3, Cycle 5, etc), clinical laboratory values will be recorded. CT scans to assess disease will be performed at the end of even-numbered cycles (Cycle 2, Cycle 4, etc).
Study identification
- NCT ID
- NCT01369433
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Tivozanib + paclitaxel Drug
- Tivozanib + temsirolimus Drug
- Tivozanib Drug
- Tivozanib (AV-951) Drug
- Tivozanib + capecitabine Drug
- Tivo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2010
- Primary completion
- May 31, 2015
- Completion
- Sep 30, 2015
- Last update posted
- Aug 31, 2020
2010 – 2015
United States locations
- U.S. sites
- 27
- U.S. states
- 21
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Translational Genomics Research Institute (TGEN) | Scottsdale | Arizona | 85258 | — |
| Institute of Urologic Oncology | Los Angeles | California | 90024 | — |
| Stanford University | Stanford | California | 94305 | — |
| Not listed | Aurora | Colorado | 80010 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33905 | — |
| H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc | Tampa | Florida | 33612 | — |
| Not listed | Beech Grove | Indiana | 46107 | — |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | — |
| Not listed | Wichita | Kansas | 57217 | — |
| Medical Oncology LLC | Baton Rouge | Louisiana | 70801 | — |
| Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC | Metairie | Louisiana | 70006 | — |
| Associates in Oncology/Hematology | Rockville | Maryland | 20850 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Not listed | Grand Rapids | Michigan | 49501 | — |
| Not listed | Tupelo | Mississippi | 38801 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Not listed | Las Vegas | Nevada | 88901 | — |
| Not listed | Lebanon | New Hampshire | 03748 | — |
| Not listed | Chapel Hill | North Carolina | 27514 | — |
| Not listed | Columbus | Ohio | 43004 | — |
| The OU Cancer Institute | Oklahoma City | Oklahoma | 73117 | — |
| Not listed | Philadelphia | Pennsylvania | 19019 | — |
| Sarah Cannon Research Institute (SCRI) | Nashville | Tennessee | 37203 | — |
| Not listed | Austin | Texas | 73301 | — |
| Coastal Bend Cancer Center | Corpus Christi | Texas | 78336 | — |
| Not listed | Dallas | Texas | 75001 | — |
| Not listed | Tacoma | Washington | 98402 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01369433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2020 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01369433 live on ClinicalTrials.gov.